2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original Research
2009
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? Expert Review Of Neurotherapeutics 2009, 9: 319-321. PMID: 19271940, DOI: 10.1586/14737175.9.3.319.Peer-Reviewed Original ResearchConceptsMultiple sclerosisRelapsing-remitting multiple sclerosisIL-12/ILPhase II clinical trialDose-ranging studyPhase I trialMechanism of actionRadiologic improvementAdvanced diseaseTherapy failsIL-23I trialIL-12/23IL-12Study inclusionPlacebo controlClinical trialsSubcutaneous injectionTreatment groupsAnimal modelsSclerosisPatientsAntibodiesTreatment effectsPhase II